These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29745059)

  • 1. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
    Tran-Duy A; Ghiti Moghadam M; Oude Voshaar MAH; Vonkeman HE; Boonen A; Clarke P; McColl G; Ten Klooster PM; Zijlstra TR; Lems WF; Riyazi N; Griep EN; Hazes JMW; Landewé R; Bernelot Moens HJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Rheumatol; 2018 Oct; 70(10):1557-1564. PubMed ID: 29745059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
    Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
    Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
    Kievit W; van Herwaarden N; van den Hoogen FH; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; van der Maas A; den Broeder AA
    Ann Rheum Dis; 2016 Nov; 75(11):1939-1944. PubMed ID: 26764260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis.
    Karpes Matusevich AR; Lai LS; Chan W; Swint JM; Cantor SB; Suarez-Almazor ME; Lopez-Olivo MA
    J Manag Care Spec Pharm; 2021 Jan; 27(1):73-83. PubMed ID: 33377443
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
    Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
    Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
    Eriksson JK; Karlsson JA; Bratt J; Petersson IF; van Vollenhoven RF; Ernestam S; Geborek P; Neovius M
    Ann Rheum Dis; 2015 Jun; 74(6):1094-101. PubMed ID: 24737786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial.
    de Jong PH; Hazes JM; Buisman LR; Barendregt PJ; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
    Rheumatology (Oxford); 2016 Dec; 55(12):2138-2147. PubMed ID: 27581208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
    van Esveld L; Cox JM; Kuijper TM; Bosch TM; Weel-Koenders AE
    Ann Rheum Dis; 2023 Oct; 82(10):1296-1306. PubMed ID: 37423648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
    Ghiti Moghadam M; Ten Klooster PM; Vonkeman HE; Kneepkens EL; Klaasen R; Stolk JN; Tchetverikov I; Vreugdenhil SA; van Woerkom JM; Goekoop-Ruiterman YPM; Landewé RBM; van Riel PLCM; van de Laar MAFJ; Jansen TL;
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):516-524. PubMed ID: 28692770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Pazmino S; Boonen A; Stouten V; De Cock D; Joly J; Van der Elst K; Westhovens R; Verschueren P
    Ann Rheum Dis; 2020 May; 79(5):556-565. PubMed ID: 32241795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
    van Mulligen E; Weel AE; Kuijper TM; Denissen NHAM; Gerards AH; de Jager MH; Lam-Tse WK; Hazes JM; van der Helm-van Mil A; de Jong PHP; Luime JJ
    Ann Rheum Dis; 2020 Dec; 79(12):1550-1556. PubMed ID: 32907801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.